A main obstacle to overcome during the treatment of tumors is drug resistance to chemotherapy; emerging studies indicate that a key factor contributing to this problem is the acidic tumor microenvironment. Here, we found that LASS2 expression was significantly lower in drug-resistant Michigan Cancer Foundation-7/adriamycin (MCF-7/ADR) human breast cancer cells than the drug-sensitive MCF-7 cells, and low expression of LASS2 was associated with poor prognosis in patients with breast cancer. Our results showed that the overexpression of LASS2 in MCF-7/ADR cells increased the chemosensitivity to multiple chemotherapeutic agents, including doxorubicin (Dox), whereas LASS2 knockdown in MCF-7 cells decreased the chemosensitivity. Cell-cycle analysis revealed a corresponding increase in apoptosis in the LASS2-overexpressing cells following Dox exposure, showing that the overexpression of LASS2 increased the susceptibility to Dox cytotoxicity. This effect was mediated by a significant increase in pH e (extracellular pH) and lysosomal pH, and more Dox entered the cells and stayed in the nuclei of cells. In nude mice, the combination of LASS2 overexpression and Dox significantly inhibited the growth of xenografts. Our findings suggest that LASS2 is involved in chemotherapeutic outcomes and low LASS2 expression may predict chemoresistance.
INTRODUCTION
Breast cancer is the most frequent malignancy in women and the second-leading cause of cancer-related deaths. 1 Chemotherapeutics are important treatments for breast cancer, and commonly used chemotherapeutic drugs including doxorubicin (Dox), MTO (mitoxantrone dihydrochloride), EPI (epirubicin hydrochloride), VRL (vinorelbine bitartrate), DDP (cisplatin) and 5-FU (5-fluorouracil). 2 However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance (MDR), remains a significant impediment to successful chemotherapy. 3 The most extensively studied mechanism underlying MDR is the overexpression of cell surface efflux pumps (for example, the ABC (ATP-binding cassette) transporter family P-glycoprotein and MDR-associated protein) that can successfully purge a wide spectrum of chemotherapeutic agents from cells, thereby decreasing their intracellular concentrations. The inhibition of ABC transporters as a method to reverse MDR in cancer patients has been studied extensively, but the results have generally been disappointing. 3, 4 Many increasing evidences show that altered pH regulation in tumor cells is involved in drug resistance. In particular, an acidic tumor microenvironment reduces the uptake of drugs such as anthracyclines, whose pK a is higher than the pH of acidic tumor microenvironment and hence ionized at acidic pH. [5] [6] [7] [8] [9] The intracellular microenvironment markedly differs between multidrug-resistant and drug-sensitive cells. In fact, resistant cells contain more acidic organelles and wider pH gradients between organelles and the cytosol than sensitive cells. 10 Dox (Adriamycin) belongs to the family of anthracyclines. It is membrane permeable in its neutral form and relatively membrane impermeable when protonated. 4 Therefore, the acid pH e (extracellular pH) of cancer cells can make Dox become protonated and hinder it from entering the cells. 11 When taken up in any of the acidic compartments of cells, Dox will also become protonated and sequestered within these compartments. 12 Chemotherapeutic agents are distributed throughout the cytoplasm and nucleus of drug-sensitive cells. In contrast, in MDR cells, they accumulate only within discrete cytoplasmic organelles, and almost none is detectable in the nucleus, the target of anthracycline drugs. 13, 14 This leads to increased drug sequestration in acidic vesicles, followed by transport to the outer cell wall and extrusion into the external medium. This is the basis of the protonation, sequestration and secretion model that has been proposed to account for the sensitivity of some tumor cells and the resistance of MDR cells to chemotherapeutic drugs.
The vacuolar-H þ -ATPase (V-ATPase) is an important pH regulatory complex in tumor cells and positively correlated to cancer invasion and metastasis, it is required to mediate signaling pathways, such as the Wnt pathway. 12, 16, 17 V-ATPase uses the energy produced by ATP hydrolysis to pump protons into the extracellular environment or into the lumen of acidic vacuoles. There is evidence that the gene encoding V-ATPase subunit C is overexpressed in MDR cell lines 18 and that the expression of V-ATPase c subunit gene is enhanced in response to anticancer agents. 19 The knockdown of the c subunit expression by small interfering RNA in Michigan Cancer Foundation-7/adriamycin (MCF-7/ADR) cells sensitizes the cells to the cytotoxicity of chemotherapeutic drugs. 8 V-ATPase inhibitors can sensitize tumor cells to various cytotoxic agents by disrupting the pH gradient between the cell cytoplasm and lysosomal compartment. 12, 20, 21 Homo sapiens longevity assurance homolog 2 of yeast LAG1 (LASS2), which is also called TMSG1 (tumor metastasis suppressor gene) or CerS2 (ceramide synthase 2), is the gene identified from a human liver cDNA library by our laboratory and interacts with VPL (proteolipid subunit of vacuolar H þ ATPase) (VPL is also designated as ATP6V0C (ATPase, H þ transporting, lysosomal 16 kDa, V0 subunit c) or ATP6L (16 kDa subunit of proton pump V-ATPase), the c subunit of V-ATPase proton pump).
22 LASS2 is one member of LASS family, including LASS1-6 23 . Recently, it has been reported that expression levels of some LASS family members are altered in breast cancer; 23, 24 however, the clinical significance of the altered expression of LASS2 in breast cancer is unknown. In this study, we found that LASS2 expression was markedly different between drug-resistant MCF-7/ADR human breast cancer cells and drugsensitive MCF-7 cells and was correlated with chemotherapeutic outcomes in patients with breast cancer, then further elucidated the molecular mechanism of LASS2 involved in chemosensitivity by the in-vitro assays and the in-vivo experiments.
RESULTS

Expression analysis of LASS2 in breast cancer cells and tissues
Among all LASS family members LASS1-6, we found that the LASS2 was obviously downregulated at mRNA level ( À 6.81-fold, Po0.001, Figure 1a ) and protein level ( À 6.91-fold, P ¼ 0.0049, Figure 1b ) in the MCF-7/ADR cells than in the parental MCF-7 cells. Next, we further confirmed the correlation between expression status of LASS2 and drug response in patients with breast cancer. The clinical and pathological characteristics for all cancer patients are detailed in Supplementary Table 1. Staining for LASS2 was observed in all tumor specimens following immunohistochemistry (Figures 1c-j show representative examples of staining patterns found within tissues). The observed LASS2 staining pattern in tumor tissues was both plasma membranous and cytoplasmic. The level and extent of staining varied from very weak focal to extensive strong expression. Comparisons between the LASS2 expression level and some tumor biology factors revealed negative relationships between LASS2 expression and lymph node metastasis and human epidermal growth factor receptor 2 (HER2) expression (P ¼ 0.033 and P ¼ 0.014, respectively) (Supplementary Table 1 ). We found a strong inverse relationship between LASS2 expression level and tumor progression (relapse/death) within 12 months (P ¼ 0.006) (Supplementary Table 1 ). Furthermore, significant associations between LASS2-positive tumors and longer disease-free survival (DFS) and overall survival (OS) were observed (P ¼ 0.006 and P ¼ 0.019, respectively) (Figures 1k and l) .
Effect of LASS2 on chemosensitivity We established stable cell lines transduced by a lentivirus carrying the LASS2 gene or no insert (vector control), which were designated as Lenti-LASS2 and Lenti-vector, respectively, in the drug-resistant breast cancer cell line MCF-7/ADR (Figure 2a) . We also established stable cell lines transduced by a lentivirus carrying LASS2-short hairpin RNA (shRNA) or ATP6V0C-short hairpin RNA, which were designated as Lenti-shRNA-LASS2 and Lenti-shRNA-ATP6V0C, respectively, in the drug-sensitive breast cancer cell line MCF-7 (Figure 2c ) or MCF-7/ADR (Supplementary Figures 1A and  B) . Overexpression of LASS2 in MCF-7/ADR cells significantly reduced the IC 50 value for Dox (P ¼ 0.0074; Figure 2b ), and LASS2 knockdown in MCF-7 cells significantly increased the IC 50 value (P ¼ 0.0260; Figure 2d ). In addition, ATP6V0C knockdown in MCF-7/ADR cells also significantly reduced the IC 50 value for Dox (P ¼ 0.0042; Supplementary Figure 1C) . Furthermore, overexpression of LASS2 in MCF-7/ADR cells increased the chemosensitivity to MTO, EPI, VRL, DDP and 5-FU (Supplementary Table 2 ).
Inhibition of V-ATPase activity The process of proton extrusion was investigated by detecting the proton concentration in the medium with pH-sensitive BCECF. As shown in Figures 3a and b , the proton secretion of Lenti-LASS2 cells was notably reduced at 9 h compared with that of Lentivector cells (P ¼ 0.0120).
The pH i (intracellular pH) recovery from intracellular acidification induced by NH 4 Cl prepulse is shown in Figures 3c-f. When exposed to NH 4 Cl, pH i increased rapidly and then decreased gradually. After the removal of NH 4 Cl, pH i dropped rapidly. In the following procedure, the pH i of control cells or Lenti-vector cells recovered (Figures 3d and e) , whereas it hardly recovered in Lenti-LASS2 cells (Figure 3f ). Under the Na þ -and HCO 3 À -free condition, pH i in control cells or Lenti-vector cells recovered, and recovery was blocked in the presence of bafilomycin A1. The results indicate that overexpression of LASS2 results in inhibition of pH i recovery due to LASS2 suppressing the function of V-ATPase through binding to ATP6V0C in Lenti-LASS2 cells.
Altered intracellular distribution of Dox in the Lenti-LASS2 cells In our examination of lysosomal acidity, the fluorescence intensity from Lenti-LASS2 cells was lower than those from Lenti-vector cells (Figures 4a and b ). This suggests that LASS2 overexpression caused an elevated lysosomal pH. To investigate the ability of the endocytic vesicles to sequester drugs, LASS2-overexpressing cells and control cells were treated with Dox (Figures 4c and d) . After uptake by MCF-7 cells, Dox was localized mostly in the nuclei, which is in line with the sensitivity of these cells to the cytotoxic effect of Dox. In contrast, Dox was localized in discrete granules in the cytosol and barely detectable in the nuclei of control and Lenti-vector cells. However, in Lenti-LASS2 cells, Dox was localized in the nuclei, as assayed by confocal fluorescence microscopy. These results indicate that increasing the lysosomal pH by lentivirus-mediated overexpression of LASS2 in MCF-7/ADR cells results in a clear nuclear targeting of Dox.
Cell cycle was arrested in the G 2 /M phase after Lenti-LASS2 cells were treated by Dox The analysis of cell-cycle distribution revealed that the overexpression of LASS2 had no effect on cell-cycle progression. After treatment with Dox, Lenti-vector cells presented evidence of a preferential block at G 2 /M phase, which was dose-dependent (G 2 /M ¼ 11.3%, 0 mg/ml; G 2 /M ¼ 22.7%, 10 mg/ml; G 2 /M ¼ 26.1%, 20 mg/ml; Supplementary Figure 2) . Furthermore, the overexpression of LASS2 significantly increased the percentage of cells arrested in G 2 /M phase due to Dox in Lenti-LASS2 cells (from 22.7 to 27.7%, 10 mg/ml; from 26.1 to 39.7%, 20 mg/ml) (Supplementary Figure 2) .
Apoptosis was enhanced after Lenti-LASS2 cells were treated by Dox Cells were treated with Dox for 24 h, and caspase-3/7 activity was measured. The results showed that caspase-3/7 activity was not significantly different between Lenti-LASS2 cells and Lenti-vector LASS2 enhances chemosensitivity S Fan et al cells when added 1, 2, 5, 10 or 15 mg/ml Dox, respectively. However, caspase-3/7 activity significantly increased in Lenti-LASS2 cells compared with control cells when the Dox was added at the concentrations of 20 or 30 mg/ml (P ¼ 0.0206 and P ¼ 0.0078, respectively) ( Figure 5a ).
Cells were treated with Dox for 48 h, and fluorescent microscopic analysis with Hoechst 33342 showed that the nuclei of cells were uniformly stained indicating unaltered nuclei when the Dox was added at the concentrations of 1 or 2 mg/ml, and there was no significant difference between Lenti-LASS2 cells and Lenti-vector cells (Figure 5b, left) . But the cells showed nuclear condensation and fragmentation when the Dox was added at the concentrations of 5, 10, 20 or 30 mg/ml. There were more cells in the Lenti-LASS2 group with nuclear condensation and fragmentation than in the Lenti-vector group (22 versus 9.5%, 5 mg/ml Dox; 34 versus 23%, 10 mg/ml Dox; 46 versus 27.7%, 20 mg/ml Dox; 52 versus 38.7%, 30 mg/ml Dox) (Figure 5b, left) . These results indicate that overexpression of LASS2 significantly enhances apoptosis induced by Dox. Similar results were obtained using the TUNEL assay to detect DNA fragmentation in the in-vivo mouse tumor model (Supplementary Figure 3) . As shown in Supplementary Figure 3 , few apoptotic cells were observed in the Lenti-vector-GFP group or Lenti-LASS2-GFP group. However, while programmed cell death occurred at low levels in the Lenti-vector-GFP þ Dox group, extensive apoptosis was observed in the Lenti-LASS2-GFP þ Dox group.
Bax belongs to the Bcl-2 family of pro-apoptotic proteins and is a key component of the mitochondrial apoptotic pathway. Upon LASS2 enhances chemosensitivity S Fan et al mitochondrial stress, Smac/Diablo is released from mitochondria and competes with caspases for binding to inhibitor of apoptosis proteins (IAPs). 25 Some IAP proteins, such as Livin, inhibit the activity of several caspases, including caspase-3, caspase-7 and caspase-9, through direct interactions. 26 Figure 5c shows that the protein levels of Bax and Smac/Diablo were significantly higher in the Lenti-LASS2 þ Dox group than in the other groups. The combination of LASS2 overexpression and Dox caused a significant decrease in the protein levels of Livin compared with the other groups (Figure 5c ). Caspase-3/7 activity significantly increased in the Lenti-LASS2 þ Dox groups compared with control cells (Figure 5a ). These results indicate that the activation of effector caspases plays a role in apoptosis induced by Dox in drugresistant cells following the overexpression of LASS2 (Figure 5d ).
Effect of LASS2 on in-vitro proliferation and migration High expression of LASS2 had no significant impact on the cancer cell proliferation within 72 h (Supplementary Figure 4A) . However, LASS2 significantly decreased the migration of MCF-7/ADR cells compared with the vector groups (Supplementary Figure 4B ; Supplementary Movies 1 and 2) . The incubation time for the migration assay was 68 h, and at that time point, the growth of MCF-7/ADR cells was not affected by LASS2 (Supplementary Figure 4A) . Therefore, the inhibitory effects on cell migration were not caused by reduced cell numbers.
Inhibition of in-vivo tumor growth For small-animal live imaging experiments, we established stable cell lines transduced by a lentivirus carrying either green fluorescent protein (GFP) plus LASS2 gene or GFP alone (vector control), which were designated as Lenti-LASS2-GFP and Lentivector-GFP, respectively, in the drug-resistant breast cancer cell line MCF-7/ADR. The overexpression of LASS2 alone or Dox treatment alone had no significant anticancer effect in the nude mouse xenografts compared with their respective control groups. The average size and weight of xenografts in the Lenti-LASS2-GFP þ Dox group were dramatically smaller and lighter than those of the Lenti-vector-GFP þ Dox group (P ¼ 0.0064 and P ¼ 0.0242, respectively) (Figures 6d and e) . Therefore, the combination of LASS2 overexpression and Dox treatment significantly inhibited the growth of the xenograft, with inhibition rates (versus the control volume and weight of the tumors) of 52.9 and 42.9%, respectively. The small-animal live imaging experiment showed that the overall GFP fluorescence intensity of the Lenti-LASS2-GFP þ Dox group was weaker than that of the Lenti-vector-GFP þ Dox group (P ¼ 0.0464) (Figure 6f ).
DISCUSSION
Evidences are accumulating that acidic tumor microenvironment is involved in cancer progression and in the tumor sensitivity to chemotherapy. [5] [6] [7] [8] [9] Among the key regulators of the acidic tumor microenvironment, V-ATPases play an important role. 27 V-ATPases have been proposed as promising molecular targets for cancer chemotherapy. 8, 12, [18] [19] [20] 27 Several V-ATPase inhibitors have been reported to sensitive tumor cells to various cytotoxic agents by disrupting the pH gradient. 12, 21 The ion trapping model predicts that chemotherapeutic drugs will accumulate in more acidic compartments. The altered pH values, including pH e in tumor microenvironment and pH of acidic vacuoles inside cancer cell, may represent a widely used mechanism to impair drug uptake 28 or to neutralize or sequester drugs into the acidic intracellular vesicles. 
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In this study, among all LASS family members (LASS1-6) we found that the mRNA level of LASS2 in the MCF-7/ADR cells was significantly lower than in MCF-7 cells ( À 6.81-fold; Figure 1a) , which is consistent with microarray results ( À 4.29-fold, GEO accession no. GSE24460) recently reported by Calcagno et al. 31 Furthermore, we confirmed this differential expression at the protein level ( À 6.91-fold; Figure 1b) . Then, we further analyzed LASS2 expression in breast cancer samples using immunohistochemistry to validate whether LASS2 expression was associated with chemotherapeutic outcomes in patients with breast cancer (Figures 1c-j) . Kaplan-Meier analysis for patients with breast cancer treated by adjuvant chemotherapy after surgery showed that lower expression of LASS2 was associated with shorter DFS and OS (Figures 1k and l) . In addition to sensitivity to chemotherapeutic drugs, there are other factors influencing prognosis of breast cancer patients. The number of specimen analyzed in this study (52 examples) may be not enough to draw the conclusion that LASS2 is a powerful predictor for clinical outcome of patients with breast cancer. More extended studies are needed to elucidate a clear link between LASS2 expression and chemosensitivity in the clinical setting. Overexpression of LASS2 in MCF-7/ADR cells could significantly reduce the IC 50 value for Dox (Figures 2a and b) . Conversely, LASS2 knockdown in MCF-7 cells significantly increased the IC 50 value (Figures 2c and  d) . These results indicate that LASS2 is involved in drug resistance in breast cancer cells.
In previous study, we reported that LASS2 could interact with VPL, also called ATP6L or ATP6V0C, the c subunit of V-ATPase proton pump. 22 In this study, we found that inhibition of V-ATPase activity by knocking down ATP6V0C expression in MCF-7/ADR cells significantly reduced the IC 50 value for Dox (Supplementary Figure 1) . These results suggest that LASS2 may enhance the chemosensitivity in cancer cells by inhibiting the V-ATPase activity through binding to ATP6V0C. To explore whether LASS2 enhance chemosensitivity by inhibiting the activity of V-ATPase proton pump through binding to ATP6V0C, we examined the influence of LASS2 on the pH e and pH i in MCF-7/ADR cells. The results showed that overexpression of LASS2 could increase the pH e (Figures 3a  and b) and decrease the pH i (Figures 3c-f ) in MCF-7/ADR cells. Meanwhile, LASS2 overexpression induced a shift of the lysosomal pH towards alkaline values (Figures 4a and b) . With increasing pH e and lysosomal pH, more Dox entered the cells (Figure 4c ) and showed a clear nuclear targeting of Dox (Figure 4d ). The LASS2 overexpression induced the increased G 2 /M phase arrest in Doxtreated MCF-7/ADR cells (Supplementary Figure 2) , it was consistent with caspase-3/7 activation and increased apoptosis Figure 5 ). Moreover, our in-vivo results in nude mice model showed the combination of LASS2 overexpression and Dox treatment caused significant decreases in tumor size and weight with respect to controls ( Figure 6 ). These results indicate that pH e in tumor microenvironment and lysosomal pH inside cancer cell are raised because LASS2 inhibits the activity of V-ATPase proton pump by binding to ATP6V0C (c subunit of V-ATPase complex, providing proton a hydrophilic path across the membrane). The in-vitro and in-vivo data reveal that LASS2 can enhance chemosensitivity by counteracting acidic tumor microenvironment and resulting in more chemotherapeutic agents to enter the cells and stay in the nuclei of cells. Considering that tumors have the acidic tumor microenvironment, drugs are easier to enter cancer cells if the protonation of drug molecules can be decreased, when the pK a of drugs is near pH e of acidic tumor microenvironment in designing chemotherapeutic agents. We also found that overexpression of LASS2 had no significant effect on the mRNA expression of MDR1/ABCB1 and BCRP/ABCG2, two important ABC transporters (Supplementary Figures 4C and  D) . Furthermore, LASS2 expression level in MCF-7 cells was not significantly different between pH 7.4 and pH 6.2 cultured conditions. Meantime, the overexpression of LASS2 decreased the rate of cell migration (Supplementary Figure 4B ; Supplementary Movies 1 and 2) and it was consistent with previous reports in which bafilomycin A1 (proton pump inhibitor) suppressed cell motility. 16, 32 This effect of bafilomycin A1 on cell motility was due to alterations of pH gradients in endocytic structures, which contain V-ATPase. 16 In addition, we found an inverse relationship in patients with breast cancer between LASS2 expression and lymph node metastasis (Supplementary Table 1 ). These data also indicate that LASS2 may play an important role in breast cancer metastasis. Further study is underway to explore the mechanism that LASS2 inhibits cancer migration and metastasis. In summary, the in-vitro data obtained from the experimental manipulation of breast cancer cell lines and the in-vivo data from the nude mice experiments first delineate molecular mechanism that LASS2 can sensitize the cells to chemotherapitic drugs. The analysis of LASS2 expression in a small amount of clinical specimens showed that low expression of LASS2 was associated with poor prognosis in breast cancer patients. Our findings suggest that LASS2 may be an indicator for chemotherapy outcomes for patients with breast cancer and imply that acidic tumor microenvironment may be considered as an influential factor of chemotherapeutic efficacy in designing chemotherapeutical drugs.
MATERIALS AND METHODS
Cell culture, chemical reagents and drugs MCF-7 breast cancer cells (American Type Culture Collection, Manassas, VA, USA; HTB-22) and MCF-7/ADR cells were cultured at 37 1C in a humidified 5% CO 2 atmosphere in RPMI-1640 medium with 10% fetal calf serum (Gibco, Invitrogen, Carlsbad, CA, USA), 100 IU/ml penicillin G, and 100 mg/ ml streptomycin sulfate (Sigma-Aldrich, St Louis, MO, USA). To maintain their resistance, MCF-7/ADR cells were cultured in the presence of a low concentration of Dox (1 mg/ml) and passaged for 1 week in drug-free medium before the experiments. 
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The chemical reagents and drugs that were used (listed in Supplementary Table 3) were diluted to the desired concentrations according to the manufacturer's protocol.
Clinical samples and immunohistochemistry staining
Fifty-two female patients who had been diagnosed with breast cancer were treated at the Xuzhou First Renmin Hospital. They received primary surgical treatment (either mastectomy or lumpectomy) without preoperative neoadjuvant therapy. After surgical treatment, all of the patients received Dox-based adjuvant chemotherapy (cyclophosphamide/Dox/ 5-FU; docetaxel/Dox/cyclophosphamide), and four or more cycles of chemotherapy were administered. Ethics approval was obtained from the local hospital ethic committees and a written consent was obtained from each patient before sample collection. Immunohistochemistry was performed for LASS2 as previously described. 33 All of the sections were observed and photographed with an IX71 inverted microscope (Olympus Corp., Tokyo, Japan). After nuclear counterstaining with hematoxylin, the cytoplasmic immunostaining intensity was categorized semiquantitatively into four groups as described previously: 34, 35 
Lentivirus production and transduction
Virus packaging was performed in HEK 293T cells after the cotransfection of pWPXL-LASS2 or pLVTHM-shRNA-LASS2 with the packaging plasmid psPAX2 (Addgene plasmid 12260, Didier Trono) and the envelope plasmid pMD2.G (Addgene plasmid 12259, Didier Trono) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Viruses were harvested 48 h after transfection. Target cells were infected with filtered lentivirus in the presence of 6 mg/ml polybrene (Sigma-Aldrich). 36 Quantitative real-time PCR Real-time PCR analyses were performed with SYBR Premix Ex Taq (TaKaRa). The primers used are given in Supplementary Table 6 .
Activity of V-ATPase Assays were performed as described previously by Lu et al. 37 
Evaluation of lysosomal acidity
The cells were incubated for 30 min at 37 1C with 500 ml pre-warmed medium containing 1 mmol/l LysoSensor Green DND-189 and analyzed by flow cytometry (Coulter EPICS XL, Beckman Coulter, Fullerton, CA, USA) collecting FL1 fluorescence. Untreated and unstained cells were used to set the background fluorescence.
To determine the localization of LysoSensor-positive vesicles, cells were incubated for 1 h at 37 1C with pre-warmed PBS containing the DND-189 and analyzed by laser scanning confocal microscopy (IX70, Olympus 60 M, Olympus), as previously described. 12, 38 Drug uptake and intracellular distribution
The cells were seeded at 1 Â 10 6 cells per 60 mm cell culture dish in complete medium. After 24 h of incubation, the culture medium was replaced with 2 ml new medium (without NaHCO 3 , pH ¼ 7). Six hours later, 20 mg Dox (Sigma-Aldrich) was added into each dish. After 4 h incubation at 37 1C, the cells were placed on ice and washed twice. The cell fluorescence was analyzed by flow cytometry and with FL2 fluorescence.
The cells were seeded at 1 Â 10 5 cells per 35 mm Â 12 mm cell culture dish with glass bottom (NEST Biotech, Hangzhou, China). After 24 h of incubation, the culture medium was replaced with 750 ml new medium (without NaHCO 3 , pH ¼ 7). Six hours later, 10 mg Dox (Sigma-Aldrich) was added into each dish. After 4 h incubation at 37 1C, the cells were fixed with 4% paraformaldehyde in phosphate buffer for 30 min at room temperature, and nuclei were stained with Hoechst 33342 (1:5000) for 10 min at 4 1C. The fluorescence of Dox incorporated into cells was visualized using laser scanning confocal microscopy.
Protein extraction and western blotting Assays were performed as described previously by Jiffar et al. 39 The antibodies are listed in Supplementary Table 7 .
Cell proliferation assay Assays were performed as described previously by Furu et al. 40 Scratch-wound assay MCF-7/ADR cells stably expressing LASS2 or the vector control cells were harvested and suspended at 0.5 Â 10 6 /ml in 1640 medium. Subsequently, 0.5 Â 10 6 cells in 1 ml of medium were then cultured in a six-well plate. Twenty-four hours later, the cells were washed with PBS and supplemented with serum-free medium for 12 h. Confluent cell monolayers were scratched using a 200-ml Finnpipette tip. The migration of cells into the wound was monitored in multiple wells using a live cell imaging workstation (LCS-IX81, Olympus Japan Co.) with a UPLSAPO10 Â 2 N.A.0.4 plan super apochromat objective. The images were acquired every hour for 68 h. The images shown represent 0 and 50 h. 41 
Xenograft model and treatments
For the in-vivo assays, 17b-estradiol pellets (NE-121, Innovative Research of America, Sarasota, FL, USA) were subcutaneously implanted into the left shoulder area of mice 3 days before tumor cell injection. MCF-7/ADR cells (1 Â 10 7 ) stably expressing LASS2 or the control vector were suspended in 100 ml serum-free 1640 and subcutaneously injected into the right upper flank of each mouse (six per group, female BALB/c-nu/nu, 8 weeks old). 42, 43 Tumor volumes were calculated as described: V (cm 3 ) ¼ width 2 (cm 2 ) Â length (cm)/2. 44 At day 11 after cell injection, mice were randomly allocated to the (1) Lenti-vector-GFP group, (2) Lenti-LASS2-GFP group, (3) Lentivector-GFP þ Dox-treated group and (4) Lenti-LASS2-GFP þ Dox-treated group. For combination experiments, mice in groups 3 and 4 were injected intraperitoneally with Dox (2 mg/kg body weight; equivalent to a dose of 6.5 mg/m 2 in patients). 45 Mice were treated twice per week for 3 weeks. At day 32 after cell injection, mice were anesthetized using 1% sodium pentobarbital (0.2 ml/20 g body weight, Sigma Chemicals, Balcatta, WA, Australia), placed in the NightOWL II LB 983 Molecular Light Imager (Berthold Technologies, Bad Wildbad, Germany), and photographed for 1.0 s using a GFP filter (GFP Ex480/20 and Em520/10) supplied with the instrument. The data were processed in WinLight software (Winlight System, Berthold Technologies). After GFP imaging, the mice were killed, and the tumors were weighed immediately after dissection. Mice were manipulated and housed according to the protocols approved by the Shanghai Medical Experimental Animal Care Commission.
Statistical analysis
The results are presented as the mean values and s.e.m. The data were subjected to Student's t-test (two-tailed; Po0.05 was considered significant) unless otherwise specified (w 2 test, Pearson's correlation, and linear regression).
